In vitro metabolism of a novel synthetic cannabinoid, EAM-2201, in human liver microsomes and human recombinant cytochrome P450s.

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Journal of Pharmaceutical and Biomedical Analysis

• Publication date

  2016-02-05

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1016/j.jpba.2015.11.023PMID 26641707
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Synthetic cannabinoids: analysis and metabolites.

  2014cited by this paper
• Determination of AM-2201 metabolites in urine and comparison with JWH-018 abuse

  2014cited by this paper
• Synthetic cannabinoids as designer drugs: new representatives of indol-3-carboxylates series and indazole-3-carboxylates as novel group of cannabinoids. Identification and analytical data.

  2014cited by this paper
• Determination of major metabolites of MAM-2201 and JWH-122 in in vitro and in vivo studies to distinguish their intake.

  2014cited by this paper
• Analytical characterization of some synthetic cannabinoids, derivatives of indole-3-carboxylic acid.

  2013cited by this paper
• A fatal case of MAM-2201 poisoning

  2013cited by this paper
• Synthetic cannabinoids abused in South Korea: drug identifications by the National Forensic Service from 2009 to June 2013

  2013cited by this paper
• Monitoring of urinary metabolites of JWH-018 and JWH-073 in legal cases.

  2013cited by this paper
• A fatal case involving several synthetic cannabinoids

  2013cited by this paper
• Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products

  2013cited by this paper
• First metabolic profile of XLR-11, a novel synthetic cannabinoid, obtained by using human hepatocytes and high-resolution mass spectrometry.

  2013cited by this paper
• URB-754: a new class of designer drug and 12 synthetic cannabinoids detected in illegal products.

  2013cited by this paper
• K2 Toxicity: Fatal Case of Psychiatric Complications Following AM2201 Exposure

  2013cited by this paper
• Identification of the major urinary metabolites in man of seven synthetic cannabinoids of the aminoalkylindole type present as adulterants in 'herbal mixtures' using LC-MS/MS techniques.

  2012cited by this paper
• Detection of urinary metabolites of AM-2201 and UR-144, two novel synthetic cannabinoids.

  2012cited by this paper
• Spice drugs are more than harmless herbal blends: a review of the pharmacology and toxicology of synthetic cannabinoids.

  2012cited by this paper
• Cytochrome P450-Mediated Oxidative Metabolism of Abused Synthetic Cannabinoids Found in K2/Spice: Identification of Novel Cannabinoid Receptor Ligands

  2012cited by this paper
• Quantitative measurement of JWH-018 and JWH-073 metabolites excreted in human urine.

  2011cited by this paper
• Identification and quantitation of a benzoylindole (2-methoxyphenyl)(1-pentyl-1H-indol-3-yl)methanone and a naphthoylindole 1-(5-fluoropentyl-1H-indol-3-yl)-(naphthalene-1-yl)methanone (AM-2201) found in illegal products obtained via the Internet and their cannabimimetic effects evaluated by in vitr

  2011cited by this paper
• Phase I Hydroxylated Metabolites of the K2 Synthetic Cannabinoid JWH-018 Retain In Vitro and In Vivo Cannabinoid 1 Receptor Affinity and Activity

  2011cited by this paper
• Screening for the synthetic cannabinoid JWH-018 and its major metabolites in human doping controls.

  2011cited by this paper
• Conjugation of Synthetic Cannabinoids JWH-018 and JWH-073, Metabolites by Human UDP-Glucuronosyltransferases

  2011cited by this paper
• Structure characterisation of urinary metabolites of the cannabimimetic JWH-018 using chemically synthesised reference material for the support of LC-MS/MS-based drug testing

  2011cited by this paper
• Themed issue: cannabinoids.

  2010cited by this paper
• Monitoring of herbal mixtures potentially containing synthetic cannabinoids as psychoactive compounds.

  2010cited by this paper
• In vitro phase I metabolism of the synthetic cannabimimetic JWH-018

  2010cited by this paper
• Detection of JWH-018 metabolites in smoking mixture post-administration urine.

  2010cited by this paper
• Identification of a cannabinoid analog as a new type of designer drug in a herbal product.

  2009cited by this paper
• 'Spice' and other herbal blends: harmless incense or cannabinoid designer drugs?

  2009cited by this paper
• Identification of a cannabimimetic indole as a designer drug in a herbal product

  2009cited by this paper
• The Drug Situation in Norway 2011 : Annual report to the European Monitoring Centre for Drugs and Drug Addiction - EMCDDA

  2009cited by this paper
• Novel benzimidazole derivatives as selective CB2 agonists.

  2008cited by this paper
• Structure-activity relationships of indole- and pyrrole-derived cannabinoids.

  1998cited by this paper
• Aminoalkylindoles: structure-activity relationships of novel cannabinoid mimetics.

  1995cited by this paper
• Cannabinoid structure-activity relationships: correlation of receptor binding and in vivo activities.

  1993cited by this paper
• Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs.

  1993cited by this paper

• In vitro metabolism of Benzyl-4CN-BUTINACA and MDMB-4CN-BUTINACA using human hepatocytes and LC-QToF-MS analysis

  2025cites this paper
• Synthesis, Labeling, and Biological Evaluation of P2Y12 Receptor Radioligands for Positron Emission Tomography Imaging of Neuroinflammation.

  2025cites this paper
• Metabolic profiling of a new synthetic cannabinoid receptor agonist, ADMB-FUBIATA, with human liver microsomes, human primary hepatocytes and human recombinant CYP450 enzymes using LC-quadrupole-orbitrap MS.

  2024cites this paper
• Elucidating a Complicated Enantioselective Metabolic Profile: A Study From Rats to Humans Using Optically Pure Doxazosin

  2022cites this paper
• Characterisation of AMB-FUBINACA metabolism and CB1-mediated activity of its acid metabolite

  2022cites this paper
• Quantitative Determination and Metabolic Profiling of Synthetic Cathinone Eutylone In Vitro and in Urine Samples by Liquid Chromatography Tandem Quadrupole Time-of-Flight Mass Spectrometry.

  2022cites this paper
• Severe Vitamin K-dependent Coagulopathy from Rodenticide-contaminated Synthetic Cannabinoids: Emergency Department Presentations

  2021cites this paper
• Urinary Metabolite Biomarkers for the Detection of Synthetic Cannabinoid ADB-BUTINACA Abuse.

  2021cites this paper
• DDDT_A_249308 1909..1919

  2020cites this paper
• Inhibitory Effect of Lygodium Root on the Cytochrome P450 3A Enzyme in vitro and in vivo

  2020cites this paper
• 3,5-Dimethyl-4-isoxazoyl selenocyanate as promising agent for the treatment of Leishmania infantum-infected mice.

  2020cites this paper
• In Vitro Metabolism of 25B-NBF, 2-(4-Bromo-2,5-Dimethoxyphenyl)-N-(2-Fluorobenzyl)ethanamine, in Human Hepatocytes Using Liquid Chromatography–Mass Spectrometry

  2019cites this paper
• In vitro and in vivo human metabolism of a synthetic cannabinoid EAM-2201 detected by LC–quadrupole-ion trap-MS/MS and high-resolution LC–Orbitrap-MS/MS

  2019cites this paper
• Characterization of in vitro metabolism of focal adhesion kinase inhibitors by LC/MS/MS

  2019cites this paper
• UPLC-HR-MS/MS-based determination study on the metabolism of four synthetic cannabinoids, ADB-FUBICA, AB-FUBICA, AB-BICA and ADB-BICA, by human liver microsomes.

  2018cites this paper
• Detection of metabolites of the new synthetic cannabinoid CUMYL-4CN-BINACA in authentic urine samples and human liver microsomes using high-resolution mass spectrometry.

  2018cites this paper
• Targeted and non-targeted metabolite identification of MAM-2201 in human, mouse, and rat hepatocytes.

  2018cites this paper
• In Vitro Inhibitory Effects of Synthetic Cannabinoid EAM-2201 on Cytochrome P450 and UDP-Glucuronosyltransferase Enzyme Activities in Human Liver Microsomes

  2018cites this paper
• In vitro metabolism of synthetic cannabinoid AM1220 by human liver microsomes and Cunninghamella elegans using liquid chromatography coupled with high resolution mass spectrometry

  2018cites this paper
• Synthetic cannabinoids are substrates and inhibitors of multiple drug-metabolizing enzymes

  2018cites this paper
• Detection of the recently emerged synthetic cannabinoid 5F-MDMB-PICA in 'legal high' products and human urine samples.

  2018cites this paper
• Metabolic characterization of (1-(5-fluoropentyl)-1H-indol-3-yl)(4-methyl-1-naphthalenyl)-methanone (MAM-2201) using human liver microsomes and cDNA-overexpressed cytochrome P450 enzymes

  2017cites this paper
• Implementation of AICAR analysis by GC-C-IRMS for anti-doping purposes.

  2017cites this paper
• Metabolic profiling of myrislignan by UPLC-ESI-QTOFMS-based metabolomics

  2017cites this paper
• Metabolic profiling of five flavonoids from Dragon's Blood in human liver microsomes using high-performance liquid chromatography coupled with high resolution mass spectrometry.

  2017cites this paper
• Is zebrafish (Danio rerio) a tool for human-like metabolism study?

  2017cites this paper
• Inhibition of cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes

  2017cites this paper
• Inhibition of cytochrome P450 and uridine 5′-diphospho-glucuronosyltransferases by MAM-2201 in human liver microsomes

  2017cites this paper
• Tentative identification of in vitro metabolites of 5-APDB, a synthetic benzofuran, by LC-Q/TOF-MS.

  2016cites this paper
• New psychoactive substances: an overview on recent publications on their toxicodynamics and toxicokinetics

  2016cites this paper